About Ascent Therapeutics
Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.
Missing: Ascent Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ascent Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Ascent Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ascent Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Ascent Therapeutics Frequently Asked Questions (FAQ)
When was Ascent Therapeutics founded?
Ascent Therapeutics was founded in 2006.
Where is Ascent Therapeutics's headquarters?
Ascent Therapeutics's headquarters is located at 161 Forest Street, Sherborn.
What is Ascent Therapeutics's latest funding round?
Ascent Therapeutics's latest funding round is Unattributed VC.
How much did Ascent Therapeutics raise?
Ascent Therapeutics raised a total of $27M.
Who are the investors of Ascent Therapeutics?
Investors of Ascent Therapeutics include Novartis Venture Funds and TVM Capital.
Who are Ascent Therapeutics's competitors?
Competitors of Ascent Therapeutics include Cevec Pharmaceuticals, Constellation Pharmaceuticals, CoImmune, Aquinox Pharmaceuticals, Regulus Therapeutics, Rigel Pharmaceuticals, Proteon Therapeutics, Sorbent Therapeutics, InterMune, iPierian and 14 more.
Compare Ascent Therapeutics to Competitors
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Altheus Therapeutics is developing Zoenasa Oral Controlled Release and Rectal Gel formulations as front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus an antioxidant to reduce bowel injury associated with IBD. Zoenasa is formulated as a rectal gel enema to improve efficacy in patients suffering from left-sided (distal) ulcerative colitis; and as oral formulations with an extended- and delayed-release profile for patients with proximal or extensive colitis.
Lead Pharma is a spinoff from the Hubrecht Institute and the University Medical Center Utrecht, developing innovative small-molecule therapies for patients with autoimmune disease or cancer.
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Femta is developing a new generation of antibody therapeutics for major disease indications.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.